OPKO receives U.S. patent allowance titled, ‘Flow Control in Microfluidic Systems’

OPKO Health, Inc. (NYSE:OPK) today announced the receipt of a patent allowance from the U.S. Patent and Trademark Office (USPTO) for the patent application titled "Flow Control in Microfluidic Systems".    

This patent describes methods for passively regulating flow in microfluidic systems. The techniques are particularly well suited for simple and portable analytical systems - such as those used in point-of-care diagnostics. Actions such as stopping and re-starting flow and controlled reaction and incubation times which would normally require complex instrumentation can be pre-programmed in the design of each microfluidic system. This enables the performance of relatively complex assays with minimal equipment. Bio-analytical procedures such as thermo-cycling for PCR, enzymatic amplification of signals in solution, and timed incubation and mixing can now be implemented in robust, easy-to-use, and cost-effective systems.

"Although this patent was intended to apply to a specific set of assays currently under development at OPKO, we view this as a particularly important enabling technology for adapting almost any laboratory test onto our platform," said Phillip Frost, M.D., OPKO's Chairman and CEO.

Source: OPKO Health, Inc.    

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.